<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02295280</url>
  </required_header>
  <id_info>
    <org_study_id>15742</org_study_id>
    <nct_id>NCT02295280</nct_id>
  </id_info>
  <brief_title>A Cost Effective Treatment for Headache in Pregnancy When Acetaminophen Alone is Ineffective.</brief_title>
  <acronym>MAD</acronym>
  <official_title>Metoclopramide and Diphenhydramine (MAD): A Cost Effective Treatment for Headache in Pregnancy When Acetaminophen Alone is Ineffective (MAD Headache Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Louis University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Louis University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if the intravenous administration of Metoclopramide and diphenhydramine in
      combination can effectively treat headaches in pregnant patients in those refractory to
      acetaminophen when compared to codeine
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, controlled study based on prospective collection of data during the
      study subjects' hospital stays, questioning at 30 minutes and 1, 6, and 24 hours after
      administration, and a post-study questionnaire at 24 hours. Subjects who agree to participate
      in the study will have already tried a standard effective dose of acetaminophen (650 to
      1000mg) without relief and are requesting further medication. Intravenous (IV) access will be
      obtained and administration of 10mg Metoclopramide IV and 25mg Diphenhydramine IV drawn up in
      the same syringe will be given to subjects randomized to Group A, while those randomized to
      Group B (control group) will receive standard treatment consisting of a codeine 30mg tablet.
      Each subject will be asked if they had relief or persistence/recurrence of symptoms at 30
      minutes, 1 hour and 6 hours after initial receipt of study medications. An additional dose of
      10 mg IV metoclopramide + 25 mg IV diphenhydramine or codeine 30 mg tablets would be given at
      one hour if the patient did not have adequate relief the first time. If headache does not
      subside or recurs after second dose, regular non protocol medicines may be administered upon
      doctor recommendation. Patients will again be asked about headache at 24 hours and asked to
      complete a questionnaire regarding tolerance of medication, any adverse reactions
      experienced, persistence/recurrence of headache after administration of study medication,
      timing of occurrence with regard to administration, requirements of a second dose of study
      medication or other use of headache or nausea medication not included in protocol,
      satisfaction or relief of headache on a Likert scale from 0 to 10 after administration of
      medication if given at 1 hr interval.

      Randomization Subjects will be randomized to GROUP A or GROUP B. An order will be placed to
      the SMHC pharmacy for the respective Group and will send up the medication assigned. The
      pharmacy will know which medications are in Group A and which are in Group B. On the pharmacy
      order sheet, the research team will indicate which group each subject is randomized to. The
      pharmacy will supply the medications and one of the nurses on the 5th floor will administer
      them.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adequate Relief of Headache as a Measure of Efficacy</measure>
    <time_frame>Primary outcome was six hours post administration</time_frame>
    <description>Number of participants with reduction in pain scores six hours post administration by at least 2 on the pain score scale.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Headache</condition>
  <arm_group>
    <arm_group_label>Metoclopramide IV &amp; Diphenhydramine IV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous (IV) access will be obtained and administration of 10mg Metoclopramide IV and 25mg Diphenhydramine IV Group A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Codeine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group B (control group) will receive standard treatment consisting of a codeine 30mg tablet.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoclopramide</intervention_name>
    <description>IV</description>
    <arm_group_label>Metoclopramide IV &amp; Diphenhydramine IV</arm_group_label>
    <other_name>metoclopramide, Reglan, Reglan ODT, Metozol ODT, Octamide,</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diphenhydramine</intervention_name>
    <description>iv</description>
    <arm_group_label>Metoclopramide IV &amp; Diphenhydramine IV</arm_group_label>
    <other_name>Benadryl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Codeine</intervention_name>
    <description>PO</description>
    <arm_group_label>Codeine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Pregnant women age 16 or older, admitted to the hospital or treated in the triage unit at
        14 weeks gestation or greater, with subjective symptoms of persistent headache despite
        650-1000 mg acetaminophen taken more than one hour before administration of study
        medication.

        Exclusion Criteria:

        Treatment with another headache-aborting medication other than acetaminophen within 24
        hours Allergy to metoclopramide, diphenhydramine, or codeine Systolic blood pressure &gt;/=
        140 Diastolic blood pressure &gt;/= 90 History of brain tumor Active diagnosis of hyperemesis
        Acute asthma exacerbation at time of presentation Active labor
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dorothea Mostello, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Louis University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Saint Louis University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2014</study_first_submitted>
  <study_first_submitted_qc>November 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2014</study_first_posted>
  <results_first_submitted>August 4, 2016</results_first_submitted>
  <results_first_submitted_qc>February 27, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">April 2, 2018</results_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Louis University</investigator_affiliation>
    <investigator_full_name>Dorothea Mostello, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>headache</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Codeine</mesh_term>
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Metoclopramide</mesh_term>
    <mesh_term>Promethazine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was a prospective randomized, controlled trial at a single perinatal care center, conducted from December 2012 through September 2014 and approved by the IRB at Saint Louis University.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Metoclopramide IV &amp; Diphenhydramine IV</title>
          <description>Intravenous (IV) access will be obtained and administration of 10mg Metoclopramide IV and 25mg Diphenhydramine IV Group A
Metoclopramide: IV
Diphenhydramine: iv</description>
        </group>
        <group group_id="P2">
          <title>Codeine</title>
          <description>Group B (control group) will receive standard treatment consisting of a codeine 30mg tablet.
Codeine: PO</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline demographic characteristics were similar between the two groups.</population>
      <group_list>
        <group group_id="B1">
          <title>Metoclopramide IV &amp; Diphenhydramine IV</title>
          <description>Normotensive pregnant women in the second or third trimester were randomized to receive either MAD intravenously (10 mg and 25 mg, respectively) or codeine (30 mg) for headache symptoms after 650-1000 mg of acetaminophen failed to relieve the headache.</description>
        </group>
        <group group_id="B2">
          <title>Codeine</title>
          <description>Normotensive pregnant women in the second or third trimester were randomized to receive either MAD intravenously (10 mg and 25 mg, respectively) or codeine (30 mg) for headache symptoms after 650-1000 mg of acetaminophen failed to relieve the headache.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
            <count group_id="B2" value="34"/>
            <count group_id="B3" value="69"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23" lower_limit="21" upper_limit="25"/>
                    <measurement group_id="B2" value="23.5" lower_limit="21" upper_limit="27"/>
                    <measurement group_id="B3" value="23" lower_limit="21" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adequate Relief of Headache as a Measure of Efficacy</title>
        <description>Number of participants with reduction in pain scores six hours post administration by at least 2 on the pain score scale.</description>
        <time_frame>Primary outcome was six hours post administration</time_frame>
        <population>Number in each arm with data at 6 hours who received either metoclopramide and diphenhydramine IV or codeine.</population>
        <group_list>
          <group group_id="O1">
            <title>Metoclopramide IV &amp; Diphenhydramine IV</title>
            <description>Number of patients who received Metoclopramide &amp; diphenhydramine IV</description>
          </group>
          <group group_id="O2">
            <title>Codeine</title>
            <description>Number of patients who received codeine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adequate Relief of Headache as a Measure of Efficacy</title>
          <description>Number of participants with reduction in pain scores six hours post administration by at least 2 on the pain score scale.</description>
          <population>Number in each arm with data at 6 hours who received either metoclopramide and diphenhydramine IV or codeine.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A sample size calculation of 35 patients in each group was based on an estimated reduction in headache pain score by at least two points, with an a of 0.05 and power of 90%, which is similar to estimates reported in prior studies in non-pregnant patients and felt to be a clinically significant decrease. Statistical analyses were performed using chi-square, Fisher's exact test for categorical variables, the independent Student's t-test and Kolmogorov-Smirnov for continuous variables.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.14</p_value>
            <p_value_desc>Reduction in pain scores by at least 2 units six hours post administration</p_value_desc>
            <method>Mann Whitney U test</method>
            <method_desc>Mann Whitney U test used for analysis of this continuous variable as data were not normally distributed. Outcome was comparable at the 6-hour mark.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 hours</time_frame>
      <desc>No SAEs</desc>
      <group_list>
        <group group_id="E1">
          <title>Metoclopramide &amp; Diphenhydramine</title>
          <description>Participants received intravenous metoclopramine (10 mg) and diphenhydramine (25 mg), up to two doses of each medication.</description>
        </group>
        <group group_id="E2">
          <title>Codeine</title>
          <description>Participants received oral 30 mg of oral codeine (up to two doses).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>One of the limitations of our study is that codeine was used as standard for comparison to the MAD regimen. This was due to poor patient enrollment with an earlier study design comparing MAD to placebo.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dorothea Mostello, MD, Maternal Fetal Medicine Faculty</name_or_title>
      <organization>Saint Louis University</organization>
      <phone>314-977-2090</phone>
      <email>mostello@slu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

